Immunic (IMUX) Earnings Analysis

Immunic (IMUX) next reports earnings on 2026-08-06, consensus EPS -1.17556 USD. Last quarter (2026-02-26) it missed with EPS -1.2 USD vs -0.9 USD est (-33.3%). It has beaten estimates in 2/4 recent quarters (50%). Trailing P/E -2.53.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does IMUX next report earnings?

Next earnings date2026-08-06
Consensus EPS estimate-1.17556 USD
Revenue estimaten/a

IMUX earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-02-26-1.2 USD-0.9 USD-33.3%Miss
2025-11-13-0.13 USD-0.18 USD+27.8%Beat
2025-05-15-0.25 USD-0.25 USD0%Beat
2025-03-31-0.25 USD-0.22 USD-13.6%Miss

Beat rate: 2/4 (50%) over reported quarters with consensus data.

IMUX valuation and analyst view

Trailing P/E-2.53
Trailing EPS-3.46051 USD
Price / book3.01
Dividend yield0.00%
Market cap0.15B
Analyst consensusBuy (10 buy / 2 hold / 0 sell)
Avg price target20.5 USD

Related research pages

Frequently asked questions

When is Immunic (IMUX)'s next earnings date?

Immunic is next scheduled to report on 2026-08-06, with a consensus EPS estimate of -1.17556 USD.

Did IMUX beat earnings last quarter?

In its 2026-02-26 report, IMUX posted EPS of -1.2 USD versus a -0.9 USD estimate — a miss of 33.3%.

What is IMUX's earnings track record?

Over the last 4 reported quarters with consensus data, IMUX beat estimates 2 times (50%).

What is IMUX's current P/E ratio and EPS?

IMUX trades at a trailing P/E of -2.53 on trailing EPS of -3.4605083221165263 USD.

What do analysts rate IMUX?

Analyst consensus is "Buy" across 12 ratings (0 strong buy, 10 buy, 2 hold, 0 sell, 0 strong sell). Average 12-month price target: 20.5 USD.